AMENDMENT

In the Specification:

On page 29, beginning at line 19, please replace lines 19-25 with the following lines:

FIG. 29A-29B. Nucleotide sequence of pRIG14. (SEQ ID NO: 21).

FIG. 30A-30C. Nucleotide sequence of pRIG19. (SEQ ID NO.: 22).

FIG. 31A-31C. Nucleotide sequence of pRIG20. (SEQ ID NO.: 23).

FIG. 32A-32C. Nucleotide sequence of pRIGad1. (SEQ ID NO.: 24).

FIG. 33A-33D. Nucleotide sequence of pRIGbd1. (SEQ ID NO.: 25).

FIG. 34A-34B. Nucleotide sequence of pUniBAC. (SEQ ID NO.: 26).

FIG. 35A-35B. Nucleotide sequence of pRIG22. (SEQ ID NO.: 27).

Please put a period after the text in lines 10 and 11 on page 130 as follows:

(g) Incubate at 4°C (hold).

(h) END.

Please put a period after the text in line 22 on page 134 as follows:

(ii) 30 cycles of 92°C denaturation for 15 sec; 60°C primer annealing for 20 sec; and 72°C primer extension for 40 sec.

Please put a period after the text in line 30 on page 140 as follows:

35) After binding collect SA-PMPs through use of a magnet and recover flow through

material (SAVE THIS MATERIAL!). In line 26, page 140, after "add" please substitute -- the-- for "he" as follows:

33) Purifying the products of the second strand reaction using the PCR cleanup kit from Qiagen. Elute in 50 µl EB and add the products of the second strand reaction to 150 µl of the PMPs.

In the Claims

Please amend the claims as follows:

62. (Once amended) A method for drug discovery comprising:

(a) integrating a vector into the genome of one or more eukaryotic cells, wherein said vector integration activates expression of an endogenous gene in said one or more cells;

(b) culturing said one or more cells under conditions favoring expression of said activated gene, thereby producing a gene product of said activated gene;

(c) screening said one or more cells for a cell in which a desired gene is activated or for a cell in which a desired phenotype is induced by said activated gene;